- Overview
- Products
- Negative Pressure Wound Therapy
- Wound Dressings and Compression
- Skin Care
- Surgical
- Vascular Access
- Sterilization Monitoring
- Temperature Management
- Adhesive Securement
- Patient Monitoring
- Respiratory Protection
- Securement and Immobilization
- Prevention
- Pressure Injuries
- Adhesive Skin Damage
- Moisture Associated Skin Damage
- Bloodstream Infections
- Hypothermia
- Tube and Line Dislodgement
- Cross Contamination
- Electrode-Related Alarm Fatigue
- Hand Hygiene
- Treatment
- Pressure Injuries
- Diabetic Foot Ulcers
- Venous Leg Ulcers
- Traumatic Wounds
- Surgical Incisions
- Open Abdomen
- Incontinence-Associated Dermatitis
- Edema and Lymphedema
- Oncology Care
- C. difficile infection
- Resources
- Education
- Support
Our apologies...
An error has occurred while submitting. Please try again.
Thank you!
Your form was submitted successfully, and a 3M rep will reach out to you.
Diabetic Foot Ulcer (DFU) solutions
Connect with a 3M Account RepresentativeEmpower your patients' healing.
Hear how 3M™ V.A.C.® Therapy can help those with diabetic foot ulcers in a segment on #TheBalancingAct, which aired on Lifetime. Watch now!
-
Research has shown that patients with diabetes have up to a 25% lifetime risk of diabetic foot ulceration (DFU), one of the most frequently recognized complications of diabetes.¹ DFUs are the leading non-traumatic cause of lower extremity foot amputations worldwide.²
Every wound is unique and may require a cascading approach to treatment. It has been demonstrated that early initiation* of our Negative Pressure Wound Therapy can reduce time to significant closure by up to 50% for acute wounds and 67% for chronic wounds.** We also offer a full suite of Advanced Wound Dressings and Skin Integrity Solutions to help your patients complete their journey to healing.
*Defined as treatment within the first 7 days for acute wound and 30 days for chronic wounds from the first wound treatment date.
** Based on a retrospective analysis conducted on a national insurance provider’s medical claims data, which examined 6,181 acute and 1,480 chronic wound patients that received NPWT from January 1, 2009 to June 30, 2011.
-
$9-13 billion in additional costsAn estimated $9-13 billion is spent to treat DFUs in the United States healthcare system annually¹.
-
15-25% lifetime riskPeople with diabetes have a 15-25% lifetime risk of developing DFUs³.
-
2.5x higher risk of deathPatients with a DFU have a 2.5x higher risk of death at five years than patients without a DFU⁴.
-
Protect skin
-
Prepare wound bed
-
Optimize wound environment
-
3M™ Dermatac™ Drape is used as an accessory to 3M™ V.A.C.™ Therapy providing peri-wound protection, an effective seal for NPWT.
-
NOTE: Specific indications, contraindications, warnings, precautions and safety information exist for these products and therapies, some of which may be Rx only. Please consult a clinician and product instruction for use prior to application.
References
1. Bradford Rice J, Desai U, et al. Burden of Diabetic Foot Ulcers for Medicare and Private Insurers. Diabetes Care 2014; 37:651–658.
2. Hingorani, A., LaMuraglia, G. M., Henke, P., Meissner, M. H., Loretz, L., Zinszer, K. M., ... & Mills Sr, J. L. (2016). The management of diabetic foot: a clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. Journal of vascular surgery, 63(2), 3S-21S.
3. Singh N, Armstrong DA, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA 2005; 293: 217-28.
4. Armstrong D, Boulton M.D., Bus S. Diabetic Foot Ulcers and Their Recurrence. N Engl J Med, 2017; 376;24.
